These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 10758053)

  • 1. Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome?
    Benhorin J; Taub R; Goldmit M; Kerem B; Kass RS; Windman I; Medina A
    Circulation; 2000 Apr; 101(14):1698-706. PubMed ID: 10758053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation.
    Windle JR; Geletka RC; Moss AJ; Zareba W; Atkins DL
    Ann Noninvasive Electrocardiol; 2001 Apr; 6(2):153-8. PubMed ID: 11333173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term flecainide therapy in type 3 long QT syndrome.
    Chorin E; Taub R; Medina A; Flint N; Viskin S; Benhorin J
    Europace; 2018 Feb; 20(2):370-376. PubMed ID: 28339995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular pharmacology of the sodium channel mutation D1790G linked to the long-QT syndrome.
    Abriel H; Wehrens XH; Benhorin J; Kerem B; Kass RS
    Circulation; 2000 Aug; 102(8):921-5. PubMed ID: 10952963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flecainide, a therapeutic option in a patient with long QT syndrome type 3 caused by the heterozygous V411M mutation in the SCN5A gene.
    Carrasco JI; Izquierdo I; Medina P; Arnau MÁ; Salvador A; Zorio E
    Rev Esp Cardiol (Engl Ed); 2012 Nov; 65(11):1058-9. PubMed ID: 22721569
    [No Abstract]   [Full Text] [Related]  

  • 6. A mutation in the sodium channel is responsible for the association of long QT syndrome and familial atrial fibrillation.
    Benito B; Brugada R; Perich RM; Lizotte E; Cinca J; Mont L; Berruezo A; Tolosana JM; Freixa X; Brugada P; Brugada J
    Heart Rhythm; 2008 Oct; 5(10):1434-40. PubMed ID: 18929331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge.
    Priori SG; Napolitano C; Schwartz PJ; Bloise R; Crotti L; Ronchetti E
    Circulation; 2000 Aug; 102(9):945-7. PubMed ID: 10961955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/Delta murine hearts modelling long QT syndrome 3.
    Stokoe KS; Thomas G; Goddard CA; Colledge WH; Grace AA; Huang CL
    J Physiol; 2007 Jan; 578(Pt 1):69-84. PubMed ID: 17023504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes.
    Viswanathan PC; Bezzina CR; George AL; Roden DM; Wilde AA; Balser JR
    Circulation; 2001 Sep; 104(10):1200-5. PubMed ID: 11535580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lidocaine attenuation testing: An in vivo investigation of putative LQT3-associated variants in the SCN5A-encoded sodium channel.
    Anderson HN; Bos JM; Kapplinger JD; Meskill JM; Ye D; Ackerman MJ
    Heart Rhythm; 2017 Aug; 14(8):1173-1179. PubMed ID: 28412158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data.
    Chorin E; Hu D; Antzelevitch C; Hochstadt A; Belardinelli L; Zeltser D; Barajas-Martinez H; Rozovski U; Rosso R; Adler A; Benhorin J; Viskin S
    Circ Arrhythm Electrophysiol; 2016 Oct; 9(10):. PubMed ID: 27733495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific Therapy Based on the Genotype in a Malignant Form of Long QT3, Carrying the V411M Mutation.
    Blich M; Khoury A; Suleiman M; Lorber A; Gepstein L; Boulous M
    Int Heart J; 2019 Jul; 60(4):979-982. PubMed ID: 31257342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Channel openings are necessary but not sufficient for use-dependent block of cardiac Na(+) channels by flecainide: evidence from the analysis of disease-linked mutations.
    Liu H; Tateyama M; Clancy CE; Abriel H; Kass RS
    J Gen Physiol; 2002 Jul; 120(1):39-51. PubMed ID: 12084774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trafficking defects and gating abnormalities of a novel SCN5A mutation question gene-specific therapy in long QT syndrome type 3.
    Ruan Y; Denegri M; Liu N; Bachetti T; Seregni M; Morotti S; Severi S; Napolitano C; Priori SG
    Circ Res; 2010 Apr; 106(8):1374-83. PubMed ID: 20339117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel mutation in SCN5A, delQKP 1507-1509, causing long QT syndrome: role of Q1507 residue in sodium channel inactivation.
    Keller DI; Acharfi S; Delacrétaz E; Benammar N; Rotter M; Pfammatter JP; Fressart V; Guicheney P; Chahine M
    J Mol Cell Cardiol; 2003 Dec; 35(12):1513-21. PubMed ID: 14654377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knock-in gain-of-function sodium channel mutation prolongs atrial action potentials and alters atrial vulnerability.
    Blana A; Kaese S; Fortmüller L; Laakmann S; Damke D; van Bragt K; Eckstein J; Piccini I; Kirchhefer U; Nattel S; Breithardt G; Carmeliet P; Carmeliet E; Schotten U; Verheule S; Kirchhof P; Fabritz L
    Heart Rhythm; 2010 Dec; 7(12):1862-9. PubMed ID: 20728579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flecainide provocation reveals concealed brugada syndrome in a long QT syndrome family with a novel L1786Q mutation in SCN5A.
    Kanters JK; Yuan L; Hedley PL; Stoevring B; Jons C; Bloch Thomsen PE; Grunnet M; Christiansen M; Jespersen T
    Circ J; 2014; 78(5):1136-43. PubMed ID: 24599044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional characterization and identification of a therapeutic for a novel SCN5A-F1760C variant causing type 3 long QT syndrome refractory to all guideline-directed therapies.
    Stutzman MJ; Gao X; Kim M; Ye D; Zhou W; Tester DJ; Giudicessi JR; Shannon K; Ackerman MJ
    Heart Rhythm; 2023 May; 20(5):709-717. PubMed ID: 36731785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel SCN5A arrhythmia mutation, M1766L, with expression defect rescued by mexiletine.
    Valdivia CR; Ackerman MJ; Tester DJ; Wada T; McCormack J; Ye B; Makielski JC
    Cardiovasc Res; 2002 Aug; 55(2):279-89. PubMed ID: 12123767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic ajmaline challenge in patients with long QT 3 syndrome caused by the most common mutation: a multicentre study.
    Hohmann S; Rudic B; Konrad T; Duncker D; König T; Tülümen E; Rostock T; Borggrefe M; Veltmann C
    Europace; 2017 Oct; 19(10):1723-1729. PubMed ID: 27915266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.